CTLA4 and infectious disease: HDTs have dramatically changed the treatment and outcomes of specific cancers (i.e. checkpoint inhibitors such as anti-PD1 or anti-CTLA4 antibodies) (Robert, 2020); unfortunately, their use in infectious diseases has limitedly reached clinical practice.